Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33746596/
1 Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China. 2 Institute of Reproductive and Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, Hunan, P.R. China.
-
Mark FeslerApril 25, 2021It will be interesting to see, now that there is an fda approved myeloma car, what the uptake of this therapy will be in the real world as providers weigh the pros/cons of RR , pfs vs cost and aes and logistical difficulty